Back to News
Market Impact: 0.28
Nutromics receives FDA Breakthrough Device Designation
Source: Business Wire
Healthcare & BiotechProduct LaunchesRegulation & LegislationTechnology & Innovation
Nutromics received FDA Breakthrough Device Designation for its first product in development, a wearable device for vancomycin therapeutic drug monitoring (TDM). The designation may accelerate regulatory engagement and development of the monitoring technology, but the announcement provides no commercialization timeline or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Meta announces $95 billion stock offering to fund AI expansion
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Apple says it will replace iPhone Duo units showing screen problems
- USTR Greer tells EU that loan to Airbus threatens trade truce on aircraft financing
- Blackstone-backed AirTrunk secures $2.98 bln green loan for Sydney campus